Karyopharm Therapeutics
Innovative Cancer Therapies
About
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company dedicated to developing groundbreaking cancer therapies. Utilizing its proprietary SINE (Selective Inhibition of Nuclear Export) technology, Karyopharm focuses on targeting cancer cells in novel ways, offering hope to patients suffering from hematologic malignancies and solid tumors. Founded with a commitment to enhancing the lives of patients, the company has made significant strides in oncology innovation, securing regulatory approvals for its first product and expanding its global presence. With a growing portfolio that includes a promising pipeline for rare diseases, Karyopharm is reshaping the landscape of cancer treatment. Headquartered in Newton, Massachusetts, Karyopharm is proud to be recognized as a Most Loved Workplace®, showcasing its dedication to employee success and satisfaction.
Karyopharm Therapeutics is a leader in developing innovative cancer therapies using advanced SINE technology.
At a Glance
Verified- Stock Symbol
- KPTI
- Revenue (2025)
- $146.1 Million
- Number of Employees
- 300
- Founded
- 2014
Most Loved Workplace®
Verified Certification Status
Earned Badges
Culture & Benefits
Core Values
Benefits & Perks
- Healthcare coverage
- Retirement savings plans
- Paid time off
- Professional development opportunities
Leadership Team
Richard Paulson
CEO
Open Positions
Company History & Milestones
Initial Public Offering
2014-10-10 - Present
Karyopharm went public, enhancing funding and visibility for its innovative cancer therapies.
FDA Approval of First Product
2021-07-01 - Present
Received FDA approval for its first drug targeting multiple myeloma.